[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO1997035573A3 - Nsaids in the treatment of pruritus - Google Patents

Nsaids in the treatment of pruritus Download PDF

Info

Publication number
WO1997035573A3
WO1997035573A3 PCT/EP1997/001561 EP9701561W WO9735573A3 WO 1997035573 A3 WO1997035573 A3 WO 1997035573A3 EP 9701561 W EP9701561 W EP 9701561W WO 9735573 A3 WO9735573 A3 WO 9735573A3
Authority
WO
WIPO (PCT)
Prior art keywords
nsaids
disclosed
treatment
pruritus
salts
Prior art date
Application number
PCT/EP1997/001561
Other languages
French (fr)
Other versions
WO1997035573A2 (en
Inventor
Justin Speight
Original Assignee
Boots Co Plc
Justin Speight
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boots Co Plc, Justin Speight filed Critical Boots Co Plc
Priority to AU21606/97A priority Critical patent/AU2160697A/en
Publication of WO1997035573A2 publication Critical patent/WO1997035573A2/en
Publication of WO1997035573A3 publication Critical patent/WO1997035573A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
    • A61K8/492—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid having condensed rings, e.g. indol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/75—Anti-irritant

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

There is disclosed use of one or more NSAIDs selected from bendazac, benzydamine, diclofenac, fenbufen, indomethacin, ketoprofen, naproxen, piroxicam, sulindac and any pharmaceutically acceptable salts thereof to treat pruritus (itching), preferably by topical administration. A non-therapeutic method of cosmetic treatment (to prevent disfigurement by suppressing the urge to scratch the itchy site) is also disclosed. Pharmaceutical compositions for this treatment are described which comprise these NSAIDs and/or their salts as an anti-pruritic agent, preferably the only anti-pruritic agent. Preferably, the anti-pruritic agent comprises from about 0.01 % to about 25 % by weight of the composition. Use of these NSAIDs and/or salts in the preparation of a medicament for treating pruritus is also disclosed.
PCT/EP1997/001561 1996-03-27 1997-03-25 NSAIDs IN THE TREATMENT OF PRURITUS WO1997035573A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU21606/97A AU2160697A (en) 1996-03-27 1997-03-25 Nsaids in the treatment of pruritus

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9606429.0A GB9606429D0 (en) 1996-03-27 1996-03-27 Pharmaceutical compositions
GB9606429.0 1996-03-27

Publications (2)

Publication Number Publication Date
WO1997035573A2 WO1997035573A2 (en) 1997-10-02
WO1997035573A3 true WO1997035573A3 (en) 1997-11-27

Family

ID=10791106

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1997/001561 WO1997035573A2 (en) 1996-03-27 1997-03-25 NSAIDs IN THE TREATMENT OF PRURITUS

Country Status (4)

Country Link
AU (1) AU2160697A (en)
GB (1) GB9606429D0 (en)
WO (1) WO1997035573A2 (en)
ZA (1) ZA972602B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6159485A (en) * 1999-01-08 2000-12-12 Yugenic Limited Partnership N-acetyl aldosamines, n-acetylamino acids and related n-acetyl compounds and their topical use
SI1031347T1 (en) 1999-01-27 2002-10-31 Idea Ag Transnasal transport/immunisation with highly adaptable carriers
FR2823751B1 (en) * 2001-04-24 2003-05-23 Oreal NOVEL COMPOUNDS OF THE FAMILY OF 3-ALKYL- (4,5 DIPHENYL- IMIDAZOL-1-YL) AND THEIR USE AS ANTI-INFLAMMATORY
US8258181B2 (en) * 2005-03-23 2012-09-04 Florida Atlantic University Treatment or prevention of cancer and precancerous disorders
AU2006228869A1 (en) 2005-03-30 2006-10-05 Astion Pharma A/S Oxaprozin or a closely related compound for the treatment of eczema
WO2015112586A1 (en) 2014-01-22 2015-07-30 Duke University Methods of treating pruritus
US10064871B2 (en) 2014-01-22 2018-09-04 Biomimetix Jv, Llc Methods of treating skin disorders
WO2024101489A1 (en) * 2022-11-11 2024-05-16 주식회사 지케이랩 Method for preparing external gel formulation containing propionic acid-based non-steroidal drug as active ingredient for treatment of itching

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0036138A2 (en) * 1980-03-06 1981-09-23 Merck & Co. Inc. Composition of matter for topical application comprising a bio-affecting agent and N,N-diethyl-m-toluamide
JPH0217115A (en) * 1988-07-06 1990-01-22 Shiseido Co Ltd Skin-beautifying cosmetic
US4952560A (en) * 1984-04-05 1990-08-28 Takeda Chemical Industries, Ltd. Ointment base
US4983385A (en) * 1985-11-22 1991-01-08 Sunstar Kabushiki Kaisha Ointment base
WO1995011017A1 (en) * 1993-10-20 1995-04-27 The Boots Company Plc Ibuprofen and flurbiprofen as anti-pruritic agents

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0036138A2 (en) * 1980-03-06 1981-09-23 Merck & Co. Inc. Composition of matter for topical application comprising a bio-affecting agent and N,N-diethyl-m-toluamide
US4952560A (en) * 1984-04-05 1990-08-28 Takeda Chemical Industries, Ltd. Ointment base
US4983385A (en) * 1985-11-22 1991-01-08 Sunstar Kabushiki Kaisha Ointment base
JPH0217115A (en) * 1988-07-06 1990-01-22 Shiseido Co Ltd Skin-beautifying cosmetic
WO1995011017A1 (en) * 1993-10-20 1995-04-27 The Boots Company Plc Ibuprofen and flurbiprofen as anti-pruritic agents

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BRACCO ET AL.: "La benzidamina nel trattamento topico della vaginite da Gardnerella vaginalis", MINERVA GINECOL., vol. 44, no. 11, November 1992 (1992-11-01), pages 573 - 584, XP000677561 *
CARBONI ET AL.: "O uso do bendazac no tratamento tŸpico de dermatites de estase", REVISTA BRASILEIRA DE MEDECINA, vol. 38, no. 7, 1981, pages 419 - 424 *
DATABASE EMBASE ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; XP002034227 *
DATABASE SCIENCE SEARCH XP002034228 *
DE GREGORIO ET AL.: "Clinical evaluation of bendazac", ACTA DERM. VENEREOL., vol. 50, no. 6, 1970, pages 466 - 468, XP000677213 *
IPPOLITO ET AL.: "Terapia delle dermatiti professionali", MINERVA MED., vol. 75, no. 19, 7 May 1984 (1984-05-07), pages 1137 - 1139, XP000677216 *
MONTEFUSCO ET AL.: "Comparazione di due schemi terapeutici a base di benzidamina nelle vaginosi batteriche", G. ITAL. OBSTET. GINECOL., vol. 13, no. 10, 1991, pages 615 - 618, XP000677562 *
PARREIRA ET AL.: "Tratamento de eczemas com bendazac, uma droga antiinflamatoria nao esteroide", FOLHA MED., vol. 85, no. 1, 1982, BRAZIL, pages 549 - 551 *
PATENT ABSTRACTS OF JAPAN vol. 0, no. 0 *

Also Published As

Publication number Publication date
ZA972602B (en) 1997-09-29
WO1997035573A2 (en) 1997-10-02
GB9606429D0 (en) 1996-06-05
AU2160697A (en) 1997-10-17

Similar Documents

Publication Publication Date Title
BR9908030A (en) Pharmaceutical composition comprising one or more orally administered dose units, and processes for preparing it, for use thereof, and for treating a medical condition or disorder in an individual in whom treatment with a cyclooxygenase-2 inhibitor is indicated
NO20013859D0 (en) Cyclooxygenase-2 inhibitor preparations that rapidly provide therapeutic effect
TR199901417T2 (en) New compositions with analgesic effect.
NO954878L (en) pyrrole
HUP9901807A3 (en) Heterocycle substituted n-acyl benzenesulfonamide derivatives, process for their preparation and their use as prodrug for the preparation of pharmaceutical compositions treating inflammation or inflammation-associated disorders
CA2105180A1 (en) Compositions containing sumatriptan
MXPA02006150A (en) Sustainedrelease formulation of a cyclooxygenase2 inhibitor.
MY111260A (en) Pharmaceutical composition for the treatment of nicotine dependence
CA2509390A1 (en) Method of treatment of prostate cancer and composition for treatment thereof
WO2001068125A3 (en) Methods and compositions for the treatment and prevention of erectile dysfunction
WO1997035573A3 (en) Nsaids in the treatment of pruritus
MY128366A (en) Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
PL323617A1 (en) Pharmaceutical preparation for treating oestrogen-dependent carcinomas
DK531089A (en) BICYCLIC IMIDAZOLE COMPOUNDS FOR USE IN TREATMENT OF HYPERALDOSTERONISM
AU8020698A (en) Use of glucosamine and glucosamine derivatives for quick alleviation of itching or localized pain
CA2156481A1 (en) 5-ht2 receptor antagonist compositions useful in treating venous conditions
WO1999045909A3 (en) Use of nitrone compounds for the inhibition of angiogenesis
CA2289017A1 (en) The use of a nitroxide or a prodrug thereof in the prophylactic and therapeutic treatment of cancer
BR0011880A (en) Method for the treatment of co-morbid conditions associated with obesity, compound, product, use of a compound, and pharmaceutical composition
JPH08505402A (en) Method for treating mucosal epidermal and epidermal pain, inflammation and infectious disease and therapeutic composition
BR0011884A (en) Method of treating obesity and comorbid conditions in a human in need of such treatment, compound of formula i, product containing compound of formula i, use of compound of formula i, and pharmaceutical composition
CA2392902A1 (en) Substituted bisindolylmaleimides for the inhibition of cell proliferation
CA2252401A1 (en) Pyridinyl-2-cyclopenten-1-ones as selective cyclooxygenase-2 inhibitors
Korstanje How to improve the risk‐benefit ratio of cyclosporin therapy for psoriasis
FR2718965B1 (en) New therapeutic application of spiramycin.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 97534048

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

122 Ep: pct application non-entry in european phase